Literature DB >> 16370559

Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.

M F Erdogan1, A Gürsoy, G Ozgen, M Cakir, F Bayram, R Ersoy, E Algün, B Cetinarslan, A Cömlekçi, P Kadioglu, M K Balci, I Yetkin, T Kabalak, G Erdogan.   

Abstract

OBJECTIVE: Medullary thyroid carcinoma (MTC) frequently occurs in a sporadic form, but a substantial number of cases are hereditary and appear as part of the multiple endocrine neoplasia type 2 (MEN2) syndromes. Germline mutations in ret proto-oncogene have been shown to be the underlying cause of MEN2 syndromes.
DESIGN: We carried out a multi-center study that aimed to perform mutational analysis of so called sporadic MTC patients.
METHODS: Fifty-six MTC patients verified by histopathologic examination were subjected to genetic analysis. Exon 10, 11, 13, 14, 15 and 16 of the ret gene were analyzed by DNA sequencing and restriction enzyme digestion method.
RESULTS: Among 56 apparently sporadic MTC patients, we identified 6 (10.7%) ret germline mutation carriers. Three individuals carried mutations at codon 634 in exon 11, one at codon 618 in exon 10, and two at codon 804 in exon 14. Identification of the predisposition gene mutation has allowed DNA-based strategy for direct mutation detection in patients with apparently sporadic MTCs. A substantial number of patients with apparently sporadic MTC carried germline mutations and 50% of their first degree relatives are expected to have or to develop MTC and/or other endocrine tumors.
CONCLUSIONS: These results indicate the importance of careful genetic surveillance of any patient with apparently sporadic MTCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16370559     DOI: 10.1007/bf03347570

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Authors:  R D Klein; D Sherman; W H Ho; D Stone; G L Bennett; B Moffat; R Vandlen; L Simmons; Q Gu; J A Hongo; B Devaux; K Poulsen; M Armanini; C Nozaki; N Asai; A Goddard; H Phillips; C E Henderson; M Takahashi; A Rosenthal
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

Review 2.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.

Authors:  A E F Vieira; M P Mello; L L K Elias; I F Lau; L M Z Maciel; A C Moreira; M Castro
Journal:  Horm Metab Res       Date:  2002-04       Impact factor: 2.936

4.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

5.  RET proto-oncogene mutations in French MEN 2A and FMTC families.

Authors:  I Schuffenecker; M Billaud; A Calender; B Chambe; N Ginet; C Calmettes; E Modigliani; G M Lenoir
Journal:  Hum Mol Genet       Date:  1994-11       Impact factor: 6.150

6.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

7.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

8.  Surgical treatment of medullary thyroid carcinoma.

Authors:  M S Cohen; J F Moley
Journal:  J Intern Med       Date:  2003-06       Impact factor: 8.989

Review 9.  Medullary thyroid carcinoma: recent advances and management update.

Authors:  D J Marsh; D L Learoyd; B G Robinson
Journal:  Thyroid       Date:  1995-10       Impact factor: 6.568

10.  Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.

Authors:  J Zedenius; G Wallin; B Hamberger; M Nordenskjöld; G Weber; C Larsson
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

View more
  6 in total

1.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

2.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Authors:  Sara Milićević; Damijan Bergant; Tina Žagar; Barbara Perić
Journal:  Croat Med J       Date:  2021-04-30       Impact factor: 1.351

3.  Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.

Authors:  Berna İmge Aydoğan; Bağdagül Yüksel; Mazhar Müslüm Tuna; Mehtap Navdar Başaran; Ayşen Akkurt Kocaeli; Melek Eda Ertörer; Kadriye Aydın; Sibel Güldiken; Yasin Şimşek; Züleyha Cihan Karaca; Merve Yılmaz; Müjde Aktürk; İnan Anaforoğlu; Nur Kebapçı; Cevdet Duran; Abdullah Taşlıpınar; Mustafa Kulaksızoğlu; Alptekin Gürsoy; Selçuk Dağdelen; Murat Faik Erdoğan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

4.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Authors:  Heather Hampel; Robin L Bennett; Adam Buchanan; Rachel Pearlman; Georgia L Wiesner
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

5.  Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

Authors:  C Romei; E Pardi; F Cetani; R Elisei
Journal:  J Oncol       Date:  2012-11-08       Impact factor: 4.375

6.  RET codon 618 mutations in Saudi families with multiple endocrine neoplasia Type 2A and familial medullary thyroid carcinoma.

Authors:  Faiza Qari
Journal:  Ann Saudi Med       Date:  2013 Mar-Apr       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.